Corticosteroid treatment and prognosis in pulmonary eosinophilia

S CAPEWELL, B J CHAPMAN, F ALEXANDER, A P GREENING, G K CROMPTON

From the Respiratory Unit, Northern General Hospital, Edinburgh, and the Medical Computing and Statistics Unit, University of Edinburgh

ABSTRACT The acute and long term responses to corticosteroid treatment in 65 patients with pulmonary eosinophilia have been reviewed. Of the 247 episodes of pulmonary eosinophilia that were documented during a median follow up period of 14 years, 186 were treated with prednisolone. Complete clearing of chest radiographic infiltrates occurred in 65% of the 247 episodes, partial clearing in 25%, and no response in 9%. Blood eosinophil counts were monitored during 194 episodes and returned to normal in 72%, decreased in 19%, and remained raised in 9%. Complete radiological clearing and a reduction in blood eosinophil counts were more common in episodes treated with prednisolone. Long term prednisolone was given to 28 of the 33 patients with allergic bronchopulmonary aspergillosis (mean 7.4 mg/day for 11 years) and to 29 of the 32 “non-aspergillosis” patients (mean 8.1 mg/day for 4-6 years). Initial pulmonary function, measured between episodes, was worse in patients with allergic aspergillosis than in those without (mean % predicted: FEV₁, 57% v 83%, vital capacity (VC) 76% v 88%). During a mean follow up period of 12 years neither group displayed further decline in FEV₁ or VC.

Introduction

Corticosteroids have been used in the treatment of pulmonary eosinophilia for over 20 years. Although recommended for acute episodes, the value of long term treatment remains the subject of much debate. Pulmonary eosinophilia tends to recur, particularly when associated with allergic bronchopulmonary aspergillosis, and permanent lung damage with pulmonary fibrosis or proximal bronchiectasis or both often results. Antifungal agents, including natamycin, nystatin, and clotrimazole, have been used but none, with the possible exception of ketoconazole, has proved effective. Inhaled corticosteroids and sodium cromoglycate improve the symptoms of chronic asthma but they do not suppress episodes of pulmonary eosinophilia in patients with allergic bronchopulmonary aspergillosis and may indeed mask them. Long term treatment with systemic corticosteroids has been advocated to prevent or reduce progressive lung damage from pulmonary eosinophilia but this has been on the basis of retrospective data, often from patients selected by virtue of secon-
method of identifying *A fumigatus* precipitins is described and definition given of asthma and atopy and of radiological evidence of fibrosis and bronchiectasis in the accompanying article. A diagnosis of allergic bronchopulmonary aspergillosis was made if an immediate skinprick test response to *A fumigatus* was positive and if serum precipitins to *A fumigatus* were present or *A fumigatus* was cultured from sputum.

**INVESTIGATIONS**

**Pulmonary eosinophilia**

An episode of pulmonary eosinophilia was defined as new radiographic pulmonary shadowing associated with a peripheral blood eosinophil count exceeding $500 \times 10^6/l$. The response to corticosteroid treatment of individual episodes of pulmonary eosinophilia was assessed clinically, haematologically, and radiologically. Clearing of chest radiographic shadowing within one month was graded as "complete," "partial," or "none," and resolution of peripheral blood eosinophilia was graded as "complete" ($<500 \times 10^6/l$), "partial" ($\geq 500 \times 10^6/l$ but significantly reduced from peak value), or "none."

**Pulmonary function**

Spirometry was performed in each patient both during and between episodes of pulmonary eosinophilia. The *initial* forced expiratory volume in one second (FEV$_1$) and vital capacity (VC) were taken as the best of the first three values recorded between episodes in each patient within a year of presentation. *Follow up* FEV$_1$ and VC in each patient were defined as the best of the last three measurements recorded during the last 12 months of follow up. Measurements for each patient were standardised as percentages of predicted values. Results were analysed by the $\chi^2$ test with Yates’s correction and Wilcoxon’s rank sum test for unpaired data.

**Results**

Sixty five patients (27 men and 38 women) with pulmonary eosinophilia were identified. Their median age was 39 years at the time of their first episode. Two hundred and fortyseven episodes of pulmonary eosinophilia were recorded during a median follow up period of 14 (range 1-31) years. Eighteen patients had single and 47 recurrent episodes. Thirty three met the criteria for allergic bronchopulmonary aspergillosis; the remaining 32 were categorised as "non-aspergillosis."

**TREATMENT FOR ACUTE EPISODES OF PULMONARY EOSINOPHILIA**

Prednisolone was given for 186 (75%) of the 247 episodes, either as a short course or as a major dosage increase (10 mg or more) above the maintenance dose.

**Capewell, Chapman, Alexander, Greening, Crompton**

Sixty episodes (32%) were treated with an initial daily dose of 5-15 mg, 86 (46%) with 20 mg, and 40 (21%) with over 20 mg/day. The proportion of episodes treated with prednisolone increased from 1960 onwards. (40–50% of episodes before 1965, 80–90% since 1980). Although symptomatic improvement was usually rapid, this proved difficult to quantify retrospectively. Response was therefore assessed in terms of clearing of chest radiographic abnormalities and resolution of peripheral blood eosinophilia.

**RADIOGRAPHIC RESPONSES TO PREDNISOLONE**

Complete clearing of the radiographic abnormalities occurred in 129 of the 186 (70%) episodes treated with prednisolone compared with only 17 of the 59 (29%) episodes not treated with prednisolone ($p < 0.001$) (fig 1). There were no differences between the radiological responses in patients with and without allergic bronchopulmonary aspergillosis.

**BLOOD EOSINOPHILIA RESPONSES TO PREDNISOLONE**

Blood eosinophil counts were recorded sequentially in 194 of the 247 episodes. Eosinophil counts returned to normal in 117 (76%) of 153 episodes treated with prednisolone compared with only 15 (37%) of 41 episodes not treated with corticosteroids ($p < 0.001$) (fig 2). The blood eosinophil count fell in all but six of 153 episodes (96%) treated with prednisolone compared with 24 of 41 episodes (59%) not treated with prednisolone. Complete resolution of eosinophilia was more common with higher doses of prednisolone (fig 2). There were no significant differences in blood eosinophil responses in patients with and without allergic bronchopulmonary aspergillosis.

![Fig 1 Clearing of chest radiographic infiltrates during episodes of pulmonary eosinophilia according to dose of prednisolone. ■ Complete radiographic response; ■ partial response; ■ no response.](http://thorax.bmj.com/ on April 12, 2017 - Published by group.bmj.com)
Corticosteroid treatment and prognosis in pulmonary eosinophilia

Fig 2 Resolution of peripheral blood eosinophilia during episodes of pulmonary eosinophilia according to dose of prednisolone. ■ Complete radiographic response; □ partial response; □ no response.

COMPARISON OF THE CLEARING OF CHEST RADIOGRAPH ABNORMALITIES AND THE BLOOD EOSINOPHILIA RESPONSE
The degree of clearing of the radiological abnormalities was associated with decrease in blood eosinophil counts. Of 153 episodes treated with prednisolone, complete clearing of the radiograph and return of blood eosinophil counts to normal values were seen in 90 (59%), a partial response in both in nine (6%), and persistent radiographic abnormality and eosinophilia in only two (1%) (table 1). Persistent radiographic shadowing with complete resolution of the eosinophilia occurred in 29 and persistent eosinophilia with radiographic clearing in 19 (table 1). In contrast, of the 41 episodes not treated with prednisolone, only nine showed complete clearing of the radiograph and complete loss of eosinophilia (p < 0.001) (table 1); eight had persistent eosinophilia and radiographic shadowing.

LONG TERM PREDNISOLONE TREATMENT
Of the total of 247 episodes of pulmonary eosinophilia, 182 were recurrences occurring in 47 patients. Ninety (49%) recurred in patients not receiving long term prednisolone treatment, 82 (45%) during prednisolone treatment with a daily dose of 10 mg or less, and 10 (6%) with a dose exceeding 10 mg daily.

Twenty eight of the 33 patients with allergic bronchopulmonary aspergillosis were treated with long term prednisolone in a mean (SD) daily dose of 7-4 (1-7) mg for a mean period of 11 years; the mean follow up was 8-1 (4-1) years. Twenty nine of the 32 "non-aspergillosis" patients received long-term prednisolone in a mean daily dose of 8-6 (4-9) years; the mean follow up was 9-6 (7-7) years.

Table 1 Clearance of radiological shadows and resolution of blood eosinophilia

<table>
<thead>
<tr>
<th>Resolution of blood eosinophilia</th>
<th>Complete</th>
<th>Partial</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>153 episodes treated with prednisolone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>90 (59)</td>
<td>21 (14)</td>
<td>8 (5)</td>
</tr>
<tr>
<td>Partial</td>
<td>17 (11)</td>
<td>9 (6)</td>
<td>3 (2)</td>
</tr>
<tr>
<td>None</td>
<td>2 (1)</td>
<td>2 (1)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>41 episodes not treated with prednisolone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>9 (22)</td>
<td>2 (5)</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Partial</td>
<td>0</td>
<td>7 (17)</td>
<td>2 (5)</td>
</tr>
<tr>
<td>None</td>
<td>1 (2)</td>
<td>8 (19)</td>
<td>8 (19)</td>
</tr>
</tbody>
</table>

SPIROMETRY
Fifty one of the 65 patients had been followed up for sufficient time to calculate change in FEV1 and VC. In 26 patients with allergic bronchopulmonary aspergillosis, mean initial FEV1, measured between episodes of pulmonary eosinophilia, was lower than that of the 25 "non-aspergillosis" patients (57% v 83% predicted; p < 0.001); initial VC values did not differ significantly (76% v 88%;) (table 2). In the 26 patients with allergic bronchopulmonary aspergillosis spirometry was performed after a mean time interval of 14-4 years after the initial measurements (range 2-23-5 years). The corresponding interval in the 25 "non-aspergillosis" patients was 9-5 (range 2-1-24-5) years. There was no significant decline in FEV1 or VC in either group. Mean FEV1 remained significantly lower in the allergic bronchopulmonary aspergillosis group (p < 0.001) (table 2).

<table>
<thead>
<tr>
<th>FEV1</th>
<th>Initial (n = 26)</th>
<th>Follow up (n = 26)</th>
<th>Mean duration of follow up (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABPA</td>
<td>57** (20)</td>
<td>61** (22)</td>
<td>14-4</td>
</tr>
<tr>
<td>Non-ABPA</td>
<td>83** (26)</td>
<td>79** (30)</td>
<td>9-5</td>
</tr>
<tr>
<td>Fibrosis or bronchiectasis* (n = 16)</td>
<td>53** (16)</td>
<td>45 (16)</td>
<td>13-1</td>
</tr>
<tr>
<td>Without fibrosis or bronchiectasis*</td>
<td>80** (30)</td>
<td>80 (35)</td>
<td>11-5</td>
</tr>
<tr>
<td>Vital capacity</td>
<td>76 (22)</td>
<td>81 (21)</td>
<td>14-4</td>
</tr>
<tr>
<td>ABPA</td>
<td>88 (21)</td>
<td>86 (22)</td>
<td>9-5</td>
</tr>
<tr>
<td>Non-ABPA</td>
<td>69** (14)</td>
<td>71 (14)</td>
<td>13-1</td>
</tr>
<tr>
<td>Fibrosis or bronchiectasis*</td>
<td>91** (25)</td>
<td>93 (29)</td>
<td>11-5</td>
</tr>
<tr>
<td>Without fibrosis or bronchiectasis*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*As assessed by chest radiograph.
**p < 0.001.
ABPA—allergic bronchopulmonary aspergillosis.

Table 2 Pulmonary function in subgroups of patients with pulmonary eosinophilia (mean (SD) % predicted values)
patients with radiographic changes suggesting fibrosis or bronchiectasis had developed persistent radiological abnormalities before starting long term prednisolone treatment and 12 before any prednisolone treatment. The development of changes suggesting fibrosis or bronchiectasis was not related to the mean long term, daily dose of prednisolone or the duration of treatment. Only three patients developed new persistent radiological changes during long term corticosteroid treatment.

Discussion

This study represents one of the largest retrospective series of patients with pulmonary eosinophilia, with a total follow up of 897 patient years. The data support the value of corticosteroid treatment for episodes of pulmonary eosinophilia, as prednisolone treatment resulted in improved clearance of chest radiographic abnormalities and reduction of blood eosinophil counts. A steroid dose effect was observed, prednisolone in excess of 20 mg a day producing resolution of blood eosinophilia and complete clearing of abnormalities on the chest radiograph more often than lower doses. Steroid response was equally good in patients with and without allergic bronchopulmonary aspergillosis. Radiographic clearing sometimes occurred in the absence of steroid treatment, as previously described.

Pulmonary eosinophilia associated with allergic bronchopulmonary aspergillosis has been reported to have a worse prognosis than cryptogenic pulmonary eosinophilia, in terms both of pulmonary function and of radiological damage. In our series the patients with allergic bronchopulmonary aspergillosis already had lower FEV1 values than those without aspergillosis at the time of clinical presentation. Radiological changes suggesting fibrosis or bronchiectasis were also already present at the time of presentation in many of the patients with allergic bronchopulmonary aspergillosis. Furthermore, during the period of follow up persistent radiological changes developed more often in the allergic bronchopulmonary aspergillosis group than in the non-aspergillosis group (9/33 v 4/32). In the patients receiving long term prednisolone treatment such changes occurred in only three, all with allergic bronchopulmonary aspergillosis.

Long term corticosteroid treatment for pulmonary eosinophilia was advocated in the belief that it could prevent recurrent episodes and subsequent lung damage. Although daily doses of 7-5 mg and 10 mg have been advocated, these were based on retrospective reviews of selected groups of patients. The rationale for long term prednisolone treatment has been somewhat ambiguous and the drug has often been given for control of symptoms of asthma rather than for the prevention of pulmonary eosinophilia. Patterson and colleagues recently recommended up to 40 mg prednisolone a day initially, to be tailed off after three to six months. Half the recurrent episodes recorded in our patients, however, occurred while they were having long term prednisolone treatment, as has been recognised previously. Many episodes of pulmonary eosinophilia are asymptomatic and may therefore go undetected unless a chest radiograph is taken by chance. In the absence of a chest radiograph symptomatic episodes of pulmonary eosinophilia may be inappropriately treated as an exacerbation of asthma or bronchial infection.

Long term corticosteroid treatment with doses exceeding 5 mg a day frequently produces major side effects and should therefore not be entertained lightly. A therapeutic nihilist might therefore use the data from our patients as evidence against long term prednisolone treatment. In contrast, the enthusiast could argue that much of the permanent radiographic abnormality and impaired pulmonary function had occurred before any steroid treatment. Furthermore, the development of new persistent radiological changes in only three patients after the start of long term prednisolone treatment and the lack of further decline in pulmonary function might both reflect benefit of treatment. Neither conclusion can be fully justified by retrospective data from Edinburgh or elsewhere. We suggest that prospective studies are urgently needed.

We thank Dr R Gibson and the clerical staff of the respiratory unit for their help and Miss J Holywell for typing the manuscript.

References

Corticosteroid treatment and prognosis in pulmonary eosinophilia


